The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells

Prostate apoptosis response-4 (Par-4) is an endogenous tumor suppressor that selectively induces apoptosis in a variety of cancers. Although it has been the subject of intensive research in other cancers, less is known about its significance in gliomas, including whether it is regulated by key drive...

Full description

Saved in:
Bibliographic Details
Published in:Acta neuropathologica 2014-11, Vol.128 (5), p.723-732
Main Authors: Liu, Yinxing, Gilbert, Misty R., Kyprianou, Natasha, Rangnekar, Vivek M., Horbinski, Craig
Format: Article
Language:English
Subjects:
AC133 Antigen
Analysis of Variance
Animals
Antigens, CD - metabolism
Apoptosis
Apoptosis Regulatory Proteins - genetics
Apoptosis Regulatory Proteins - metabolism
Brain cancer
Brain Neoplasms
Cancer
Cell Line, Tumor
Chemotherapy
Dehydrogenases
Disease Models, Animal
DNA Methylation
Enzyme kinetics
Flow Cytometry
Gene Expression Regulation, Neoplastic - genetics
Genetic aspects
Genomics
Glioma - pathology
Gliomas
Glycoproteins - metabolism
Green Fluorescent Proteins - genetics
Green Fluorescent Proteins - metabolism
Health aspects
Humans
Isocitrate Dehydrogenase - genetics
Kinases
Medical prognosis
Medicine
Medicine & Public Health
Mutation
Mutation - genetics
Neoplastic Stem Cells - pathology
Neurosciences
Original Paper
Pathology
Peptides - metabolism
Prostate
Proteins
Radiation
RNA
RNA, Messenger
Stem cells
Tissue Array Analysis
Transplantation, Heterologous
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate apoptosis response-4 (Par-4) is an endogenous tumor suppressor that selectively induces apoptosis in a variety of cancers. Although it has been the subject of intensive research in other cancers, less is known about its significance in gliomas, including whether it is regulated by key driver mutations, has therapeutic potential against glioma stem cells (GSCs), and/or is a prognostic marker. We found that patient-derived gliomas with mutant isocitrate dehydrogenase 1 have markedly lower Par-4 expression ( P  
ISSN:0001-6322
1432-0533
DOI:10.1007/s00401-014-1334-7